PAP assays in newborn screening for cystic fibrosis: A population-based cost-effectiveness study

Journal of Medical Screening

Volumn 23, Issue 2, 2016, Pages 62-69

  Seror, Valerie ^a,b   Cao, Caroline ^a,b   Roussey, Michel ^c,d   Giorgi, Roch ^a,b  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Association française pour le dépistage La prévention des handicaps de l'enfant AFDPHE   (France)

Author keywords

Cost effectiveness; Cystic fibrosis; Micro costing; Newborn screening; PAP assay

Indexed keywords

CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LECTIN; PANCREATITIS-ASSOCIATED PROTEIN; TRYPSINOGEN; TUMOR ANTIGEN; TUMOR MARKER;

BLOOD; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; ECONOMICS; EVALUATION STUDY; FEMALE; FRANCE; GENETICS; HUMAN; MALE; NEWBORN; NEWBORN SCREENING; PROCEDURES; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FRANCE; HUMANS; INFANT, NEWBORN; LECTINS, C-TYPE; MALE; NEONATAL SCREENING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN;

EID: 84978634391     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141315599421     Document Type: Article

References (30)

1. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53:1-36.
2. Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis 2012;35:603-11.
3. Nshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge AM, Fournier D, et al. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study. J Cyst Fibros 2014;13:267-74.
4. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979;1:472-4.
5. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-80.
6. McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M. 'It is not in my world': an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 2008;16:435-44.
7. Moffett A, Ross LF. A pilot study to determine whether health care professionals perceive stigma in heterozygote carrier identification and disclosure decisions. Am J Med Genet A 2011;155A:1897-905.
8. Roussey M, Le Bihannic A, Scotet V, Audrezet MP, Blayau M, Dagorne M, et al. Neonatal screening of cystic fibrosis: diagnostic problems with CFTR mild mutations. J Inherit Metab Dis 2007;30:613.
9. Ciske DJ, Haavisto A, Laxova A, Rock LZ, Farrell PM. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. Pediatrics 2001;107:699-705.
10. Henneman L, Bramsen I, van der Ploeg HM, Ader HJ, van der Horst HE, Gille JJ, et al. Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 2001;38:695-703.
11. Vernooij-van Langen AM, Reijntjens S, van der Pal SM, Loeber JG, Dompeling E, Dankert-Roelse JE. To know or not to know, disclosure of a newborn carrier screening test result for cystic fibrosis. Eur J Med Genet. 2013.
12. Iovanna JL, Ferec C, Sarles J, Dagorn JC. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis. C R Acad Sci III 1994;317:561-4.
13. Sarles J, Berthezene P, Le Louarn C, Somma C, Perini JM, Catheline M, et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005;147:302-5.
14. Krulisova V, Balascakova M, Skalicka V, Piskackova T, Holubova A, Paderova J, et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/ PAP and IRT/PAP/DNA. Eur J Pediatr 2012;171:1223-9.
15. Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010;33:S263-71.
16. Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ, Van der Ploeg CP, et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012;67:289-95.
17. Cornel MC, Gille JJ, Loeber JG, Vernooij-van Langen AM, Dankert-Roelse J, Bolhuis PA. Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011. J Inherit Metab Dis 2012;35:635-40.
18. Sarles J, Giorgi R, Berthezene P, Munck A, Cheillan D, Dagorn JC, et al. Neonatal screening for cystic fibrosis: Comparing the performances of IRT/ DNA and IRT/PAP. J Cyst Fibros 2014;13:384-90.
19. Drummond M, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programs. 2nd ed. New York: Oxford University Press, 1997.
20. Luce B, Manning W, Siegel J, Lipscomb J. Estimating costs in cost-effectiveness analysis. New York: Oxford University Press, 1996.
21. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
22. Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009;8:153-73.
23. Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 2009;123:e338-46.
24. Ross LF. Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr 2008;153:308-13.
25. Scotet V, de Braekeleer M, Roussey M, Rault G, Parent P, Dagorne M, et al. Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis. Lancet 2000;356:789-94.
26. Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr 2005;147:S101-5.
27. Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007;369:1187-95.
28. van den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006;118:896-905.
29. Wells J, Rosenberg M, Hoffman G, Anstead M, Farrell PM. A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis. Pediatrics 2012;129:e339-47.
30. Ranieri E. Newborn screening in Australia, investigating alternative strategies such as PAP 36th European Cystc Fibrosis Conference Lisbon, Portugal 2013.